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Alkaloid inspired spirocyclic oxindoles from 1,3-dipolar
cycloaddition of pyridinium ylides†
Jonathan Day,a Maliha Uroos,a Richard A. Castledine,a William Lewis,a
Ben McKeever-Abbasb and James Dowden*a
Cycloaddition reactions between pyridinium ylides and 3-alkenyl oxindoles that proceed in high yield
and with very good regio- and diastereoselectivity are reported. The resulting cycloadducts have the
same stereochemistry of biologically active oxindole alkaloids, such as strychnofoline.
Introduction
Natural products and their signature fragments are an endur-
ing resource for identifying biological modulators.1 A number
of biologically active alkaloids, such as strychnofoline and iso-
rhynchophylline (Fig. 1), feature spiroindolizidine oxindoles.2,3
This fragment is considered ‘privileged’ for potential thera-
peutic investigation and there is much interest in developing
expedient synthesis of such structures.4
Target spiroindolizidineoxindole structures may be eﬃcien-
tly accessed by 1,3-dipolar cycloaddition of 3-alkylideneindo-
line-2-ones.5 Serov et al. described reactions between N-phenylacyl-
quinolinium ylides with 3-alkylidene oxindoles,6 while
extended studies of this type of reaction have recently
been reported.7 The latter cycloadducts have a relatively high
molecular weight due to additional aromatic rings and it is
not easy to envisage strategies for their transformation into
natural products or drug-like scaﬀolds.
There are no literature descriptions of corresponding 1,3-
dipolar cycloadditions of pyridinium ylides to 3-alkylidene ox-
indoles, yet such cycloadducts would be attractive for access to
spirooxindole alkaloids and possible therapeutics. Cyclo-
addition reactions of pyridinium ylides have previously been
reported but in situ oxidation is commonly used, leading to
valuable unsaturated indolizines.8 Of course, such oxidations
destroy the rich stereochemical information accumulated
during the cycloaddition. Early investigation of general pyridi-
nium ylide cycloadditions noted limited stability of the tetra-
hydroindolizine cycloadducts and this may have discouraged
further investigation of these products.9 The 1,2-dihydro-
pyridine motif embedded within tetrahydroindolizine cyclo-
adducts is generally regarded as unstable with few exceptions,10
although there have been exciting developments in unlocking
their synthetic potential.11
This report demonstrates that cycloaddition reactions
between pyridinium ylides 2 (Table 1) and 3-alkylidene oxindoles
Fig. 1 Example spirooxindole alkaloids.
Table 1 Optimisation of conditions
Solvent Base Time (h) Yielda (%)
Toluene Et3N 3 65
EtOAc Et3N 4 64
CH2Cl2 Et3N 2 88
DMF Et3N 1 61
EtOH Et3N 4 40
CH2Cl2 DBU 3 73
CH2Cl2
tBuOK 3 71
THF NaH 2 82
a Yield after chromatography.
†Electronic supplementary information (ESI) available: Full experimental and
spectroscopic information. CCDC 927102–927103. For ESI and crystallographic
data in CIF or other electronic format see DOI: 10.1039/c3ob41415a
aSchool of Chemistry, University of Nottingham, University Park, Nottingham, NG7
2RD, UK. E-mail: james.dowden@nottingham.ac.uk; Fax: +44 (0)115 9513565;
Tel: +44 (0)115 9513566
bPharmaceutical Development, AstraZeneca, Silk Road Business Park, Macclesfield,
UK
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1 proceed with good selectivity to produce generally isolable spiro-
tetrahydroindolizineoxindole cycloadducts 3 in good yield.
Results and discussion
Starting materials for this route are readily accessible by olefi-
nation of isatin to give 3-alkylidene-2-oxindoles;12† pyridinium
salts were obtained by alkylation.13† Pyridinium salts featuring
N-methylene groups attached to an electron withdrawing
group can be readily deprotonated using mild base to give the
ylide.14,15
Initially, we set out to briefly investigate the role of solvent
and base on yield. An excess of pyridinium salt 2a relative to
dipolarophiles 1a was used to suppress further cycloaddition
onto the initial tetrahydroindolizine product.9
Generally, high yields of cycloadduct were obtained using a
variety of solvents and base at room temperature, although
suspending the reagents in dichloromethane, then initiating
the reaction by addition of triethylamine is convenient
(Table 1). The cycloadduct 3a is stable to chromatography and
could be stored under argon in the freezer for no more than a
week.
Cycloaddition between the ylide derived from 3-bromo-
pyridinium salt 2a and oxindole 1a appears to be highly regio-
and diastereoselective, giving a single product 3a (Table 1).
1H-NMR spectroscopy of the cycloadduct revealed an
apparent triplet for the 5′ proton ( J = 7.0 Hz) indicative of reac-
tion at the C-2 position of the pyridinium salt. Initial NOESY
analysis revealed enhancements between protons corres-
ponding to 1′ ring junction and 2′ position adjacent to the
spirocentre, but not between the 1′ and 3′ positions adjacent
to nitrogen.
Ultimately, single crystal X-ray diﬀraction of this material
gave unequivocal evidence of the diastereoselectivity of the
reaction (Fig. 2).‡ The relative stereochemistry of the spiro-
centre (position 8a′) and the 1′ position is diagnostic of exo or
endo selectivity; co-location of the oxindole carbonyl and 1′
proton on the same face of the cycloadduct is suggestive of an
attractive interaction between the electron rich oxindole aro-
matic ring and the electron deficient pyridinium in the tran-
sition state. The trans arrangement of the 1′ and 3′ protons is
also confirmed, indicating that the ylide is S-shaped in the
transition state (Scheme 1). This relative stereochemistry is the
same as that required for alkaloids related to strychnofoline
and isorhynchophylline.
We next carried out investigation into the generality of the
reaction using various 3-alkylideneoxindoles 1b–f (Table 2).11†
Cycloaddition with the ylide derived from 3-bromopyridinium
salt 2a generally proceeded to give good yields (80–90%) of
cycloadducts 3b–f as single diastereoisomers with relative
stereochemistry similar to cycloadduct 3a as judged by 1H
NMR spectroscopy. 3-Methylene oxindole 1f is a stable solid
that readily undergoes cycloaddition reactions in good yield
(entry 5). Unfortunately, N-substituted 3-methylene oxindoles
are highly reactive and generally met with polymerisation
before cycloaddition could be attempted.16 On the other hand,
N-propargyl and N-acetyl substituted oxindoles (entries 3 and
4, 1d and 1e respectively) bearing an ethyl ester gave good
yields of cycloadducts (3d and 3e respectively).
A selection of pyridinium salts (2g–l) were also evaluated
(Table 3). Cycloadducts arising from reaction with unsubsti-
tuted pyridinium salt (2l) could be detected by mass spectro-
metry of the reaction mixture but were not stable to
purification by chromatography, however the saturated indol-
izidine 3l could be obtained by in situ reduction using
RANEY® nickel in good yield.
Pyridinium salts featuring methyl, or phenyl substituents at
the 3- or 4-pyridinium position (not shown) did not give obser-
vable products in their respective cycloaddition reactions
using these condition, which we presume to be due to their
instability.
Pleasingly, less acidic pyridinium salts featuring either
nitrile (2m) or phenyl (2n) ylide stabilising groups could be
deprotonated with sodium hydride, leading to good yields of
the corresponding cycloadducts 3m and 3n respectively as
single diastereoisomers (Scheme 2).
Pyridinium salts featuring resonance stabilising groups
(2g–i) in the 3-position gave good overall yields of spiroindol-
izidine oxindoles arising from reaction at the C-6 position of
the pyridinium ring, i.e. opposite to the electron withdrawing
substituent. These products (3g–i) were obtained as a mixture
of two diastereoisomers in varying ratios.
Scheme 1 Proposed origin of observed diastereoselectivity.
Fig. 2 Crystal structure of cycloadduct 3a (CCDC 927103). Ellipsoids are drawn
at the 50% probability level.
‡Crystal data for 3a. C21H21BrN2O5, M = 507.38, triclinic, a = 8.5537(12), b =
9.0560(14), c = 16.2097(17) Å, U = 1147.4(3) Å3. T = 120(2)K, space group P1ˉ, Z =
2, 8522 reflections measured, 4490 unique with R = 0.0804, wR2 = 0.2241. CCDC
927103. Crystal data for 3g′. C19H17N3O3, M = 335.35, triclinic, a = 8.8865(5), b =
9.3125(3), c = 10.9460(5) Å, U = 826.26(7) Å3. T = 120(2) K, space group P1ˉ, Z = 2,
15 441 reflections measured, 3480 unique with R = 0.0346, wR2 = 0.0903. CCDC
927102.
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Crystals were obtained from the 3-cyanopyridine derived
cycloadduct 3g that X-ray diﬀraction revealed to feature the 1′
proton on the opposite face to the oxindole carbonyl (Fig. 3).‡
This product was later confirmed as the minor diastereoisomer
3g′ by 1H NMR spectroscopy.
There are two possible explanations for these observed
results. One is that pyridinium resonance stabilising groups
influence the orientation of the transition state. Alternatively,
interconversion of cycloadducts via ring opening to restore the
pyridinium ring, then rotation about the former 2′–8′a bond
and rejoining of the enolate with the pyridinium may
proceed.17 An analogous reversible Mannich reaction mechan-
ism is well known to occur in either acidic or basic media,
leading to interchange between related spirocyclic oxindole
alkaloid diastereoisomers, such as isorhynchophylline and
Table 2 Cycloaddition with varied oxindoles
Entry Oxindole Cycloadduct Yielda (%)
1 93
2 91
3 82
4 83
5 81
a Yield after chromatography.
Table 3 Cycloaddition with various pyridinium salts
Entry Pyridinium salt Cycloadduct Yielda (%) [ratio]
1 77 [2 : 1]b
2 95 [7 : 3]b
3 81 [1 : 1]b
4 76
5 87
6 63c
a Yield after chromatography. b Inseparable mixture of two
diastereoisomers, ratio in parenthesis from relative integration of 1H
NMR spectrum. c Crude cycloadduct subject to H2/RANEY® nickel
(∼10 mol%) in EtOAc.
Scheme 2 Reagents and conditions: a, NaH (2 equiv.), THF, rt.
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rhynchophylline.18 Diastereoisomer 3g′ remained unchanged
when exposed to the same cycloaddition conditions for
14 hours, however.19
A recent paper described reactions of very closely related
pyridinium ylides and 3-alkylideneoxindoles in ethanol with
20 mol% triethylamine at 50 °C, but alkene products arising
from elimination of pyridine were the exclusive reported pro-
ducts.20 A similar reaction product was obtained when the
cycloaddition reaction between pyridinium ylide 2l with 3-alkyl-
ideneoxindole 1a was performed in ethanol at room tempera-
ture, resulting in clean conversion to the elimination product
5 in 60% yield (Scheme 3). Presumably, the reaction proceeds
via 1,4-conjugate addition and not cycloaddition, with sub-
sequent elimination of pyridine.21,22
Significantly, crude cycloadduct 4 obtained from cyclo-
addition in dichloromethane at room temperature did not
undergo elimination when stirred in ethanol with triethyl-
amine. This result, when considered alongside the observation
for cycloadduct 3g′ above, suggests that the reversible mechan-
ism is not occurring in these cases. Overall, these studies
underline that, for these reagents, cycloaddition and 1,4-conju-
gate addition reaction outcomes are under the subtle influence
of solvent.
Conclusions
In summary, 1,3-dipolar cycloadditions between pyridinium
ylides and 3-alkenyloxindoles that give spiroindolizidine oxi-
ndole products in high yield and with excellent regioselectivity
and diastereoselectivity are reported for the first time. These
cycloadducts are highly reminiscent of biologically active
alkaloids, especially isorhynchophylline and strychnofoline.
Specific modification of this general cycloaddition route to
facilitate highly convergent access to such alkaloids and
related targets is underway.
Experimental
General information
Experimental describing precursor preparation is included
within the ESI.†
General procedure for preparation of cycloadducts (3). Base
(2 equiv.) was added to pyridinium salt (2 equiv.) in dry
solvent, under argon and the mixture stirred at room tempera-
ture for 5 minutes. Oxindole (1 equiv.) was added and the
mixture stirred at room temperature for 2–4 hours. Water was
added and the organic layer separated, washed with water (2×),
brine, dried over Na2SO4, filtered and evaporated. The crude
products were purified by column chromatography on silica
gel (using either MeOH–CH2Cl2; 1/10 or EtOAc–petrol; 1/1 as
eluent) or recrystallised with ethanol.
(1′R*,2′S*,3′S*,8a′S*)-Diethyl 8′-bromo-2-oxo-3′,8a′-dihydro-
2′H-spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate (3a). Brown
solid; 121 mg (88%); m.p. 76–78 °C; IR (νmax/cm
−1, CHCl3)
3442, 3136, 2984, 2482, 1734, 1639, 1622, 1563, 1471, 1372,
1340, 1249, 1191; NMR δH (400 MHz, d
6-DMSO) 10.68 (1H, br
s, NH), 7.26–7.22 (1H, m, ArH), 7.17 (1H, d, J = 7.4 Hz, ArH),
6.91 (1H, m, ArH), 6.86 (1H, d, J = 7.4 Hz, ArH), 6.61 (1H, d, J =
7.0 Hz, N–CHvCH), 6.10 (1H, d, J = 7.0 Hz, CH–CHvCBr),
5.06 (1H, d, J = 7.0 Hz, NCH(CO2Et), 5.00 (1H, s, NCHC–Br),
4.45 (1H, app t, J = 7.0 Hz, NCHvCH), 4.21 (2H, q, J = 7.1 Hz,
NCHCO2CH2CH3), 3.65 (2H, q, J = 7.1 Hz, CCH(CO2CH2CH3)),
3.45 (1H, d, J = 7.0 Hz, CCH(CO2Et), 1.23 (3H, t, J = 7.1 Hz,
NCHCOCH2CH3), 0.62 (3H, t, J = 7.1 Hz, CCO2CH2CH3); NMR
δC (100 MHz, d
6-DMSO) 176.2 (C), 171.4 (C), 168.4 (C), 144.0
(C), 134.9 (CH), 129.5 (CH), 128.9 (CH), 126.5 (C), 124.7 (CH),
121.5 (CH), 109.9 (CH), 106.9 (C), 93.2 (CH), 72.6 (CH), 64.8 (CH),
64.2 (C), 62.0 (CH2), 61.4 (CH2), 52.8 (CH), 14.5 (CH3), 13.5 (CH3);
m/z (HRMS-ESI+) 461.0697 (M + H C21H22
79BrN2O5 requires
461.0712), 463.0700 (M + H C21H22
81BrN2O5 requires 463.0692).
(1′R*,2′S*,3′S*,8a′S*)-Diethyl 5,8′-dibromo-2-oxo-3′,8a′-dihydro-
2′H-spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate (3b). Brown
solid; 85 mg (93%); m.p. 68–70 °C; IR (νmax/cm
−1, CHCl3)
3437, 2982, 1732, 1639, 1618, 1564, 1465, 1373, 1309, 1130;
NMR δH (400 MHz, d
6-acetone) 9.84 (1H, br s, NH), 7.45–7.41
(2H, m, ArH), 6.95 (1H, dd, J = 8.2, 0.4 Hz, ArH), 6.61 (1H, d,
J = 7.1 Hz, N–CHvCH), 6.14 (1H, app dt, J = 6.4, 1.0 Hz, CH–
CHvCBr), 5.20 (1H, d, J = 1.0 Hz, NCHCBr), 5.05 (1H, d, J = 6.6
Hz, NCH(CO2Et), 4.58 (1H, dd, J = 7.1, 6.4 Hz, NCHvCH), 4.27
Fig. 3 Crystal structure of the minor diastereoisomer of cycloadduct 3g’ (CCDC
927102). Ellipsoids are drawn at the 50% probability level.
Scheme 3 Reagents and conditions: a, Et3N (2 equiv.), ethanol, rt, 60%; b, Et3N
(2 equiv.), CH2Cl2, rt.
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(2H, q, J = 7.1 Hz, NCHCO2CH2CH3), 3.76 (2H, q, J = 7.1 Hz,
CCHCO2CH2CH3), 3.69 (1H, d, J = 6.6 Hz, CCHCO2Et), 1.29
(3H, t, J = 7.1 Hz, NCHCOCH2CH3), 0.78 (3H, t, J = 7.1 Hz,
CCHCO2CH2CH3); NMR δC (100 MHz, d
6-acetone) 175.3 (C),
170.6 (C), 168.0 (C), 143.0 (C), 134.0 (CH), 131.9 (CH), 129.0
(C), 128.8 (CH), 127.5 (CH), 113.3 (C), 111.3 (CH), 106.8 (C),
93.3 (CH), 72.8 (CH), 64.8 (CH), 64.4 (C), 61.6 (CH2), 61.1
(CH2), 52.8 (CH), 13.6 (CH3), 12.9 (CH3); m/z (HRMS-ESI+)
538.9808 (M + H C21H21
79Br2N2O5 requires 538.9812), 540.9806
(M + H C21H21
81Br2N2O5 requires 540.9792).
(1′R*,2′S*,3′S*,8a′S*)-Diethyl 8′-bromo-5-nitro-2-oxo-3′,8a′-
dihydro-2′H-spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate
(3c). Yellow solid; 88 mg (91%); m.p. 83–85 °C; IR (νmax/cm
−1,
CHCl3) 3249, 2981, 1745, 1626, 1603, 1455, 1343, 1125; NMR δH
(400 MHz, d6-acetone) 10.30 (1H, br s, NH), 8.28 (1H, dd, J = 8.7,
2.3 Hz, ArH), 8.17 (1H, d, J = 2.3 Hz, ArH), 7.22 (1H, d, J = 8.7
Hz, ArH), 6.70 (1H, d, J = 7.1 Hz, N–CHvCH), 6.15 (1H, d, J =
6.4 Hz, CH–CHvCBr), 5.27 (1H, s, NCHC–Br), 5.15 (1H, d, J =
6.5 Hz, NCH(CO2Et)), 4.62 (1H, dd, J = 7.1, 6.4 Hz, NCHvCH),
4.28 (2H, q, J = 7.1 Hz, NCHCO2CH2CH3), 3.77 (1H, d, J = 6.5
Hz, CCH(CO2Et)), 3.76 (2H, q, J = 7.1 Hz, CCH(CO2CH2CH3)),
1.30 (3H, t, J = 7.1 Hz, NCHCOCH2CH3), 0.77 (3H, t, J = 7.1 Hz,
CCH(CO2CH2CH3)); NMR δC (100 MHz, d
6-acetone) 176.0 (C),
170.4 (C), 167.9 (C), 149.9 (C), 142.4 (C), 134.0 (CH), 129.1 (CH),
127.5 (C), 126.3 (CH), 120.2 (CH), 109.7 (CH), 106.4 (C), 93.6
(CH), 73.2 (CH), 65.0 (CH), 64.2 (C), 61.7 (CH2), 61.4 (CH2), 52.8
(CH), 13.6 (CH3), 12.9 (CH3); m/z (HRMS-ESI+) 506.0569 (M + H
C21H21
79BrN3O7 requires 506.0558), 508.0552 (M + H C21H21-
81BrN3O7 requires 508.0537).
(1′R*,2′S*,3′S*,8a′S*)-Diethyl 8′-bromo-5-methoxy-2-oxo-1-
(prop-2-yn-1-yl)-3′,8a′-dihydro-2′H-spiro[indoline-3,1′-indol-
izine]-2′,3′-dicarboxylate (3d). Grey solid; 74 mg (82%);
m.p. 125–127 °C (ethanol); IR (νmax/cm
−1, CHCl3) 3309, 3011,
1738, 1718, 1639, 1605, 1495, 1370, 1339, 1192; NMR δH
(400 MHz, d6-acetone) 7.07 (1H, d, J = 8.5 Hz, ArH), 6.99 (1H,
d, J = 2.4 Hz, ArH), 6.94 (1H, dd, J = 8.5, 2.4 Hz, ArH), 6.61 (1H,
d, J = 7.1 Hz, N–CHvCH), 6.08 (1H, dt, J = 6.4, 0.9 Hz, CH–
CHvCBr), 5.21 (1H, d, J = 0.9 Hz, NCHC–Br), 5.06 (1H, d, J =
6.9 Hz, NCH(CO2Et)), 4.63 (1H, d, J = 17.8, 2.6 Hz, NCHaHb),
4.57 (1H, dd, J = 7.1, 6.4 Hz, NCHvCH), 4.50 (1H, d, J = 17.8,
2.5 Hz, NCHaHb), 4.27 (2H, q, J = 7.1 Hz, NCHCO2CH2CH3),
3.74 (3H, s, OCH3), 3.73 (1H, d, J = 6.9 Hz, CCH(CO2Et), 3.72
(2H, q, J = 7.1 Hz, CCH(CO2CH2CH3)), 2.80 (1H, dd, J = 2.6, 2.5
Hz, CuCH), 1.30 (3H, t, J = 7.1 Hz, NCHCOCH2CH3), 0.73
(3H, t, J = 7.1 Hz, CCH(CO2CH2CH3)); NMR δC (100 MHz,
d6-acetone) 172.8 (C), 170.7 (C), 167.9 (C), 155.6 (C), 137.0 (C),
133.9 (CH), 128.5 (CH), 126.9 (C), 113.3 (CH), 111.8 (CH), 109.3
(CH), 106.4 (C), 93.3 (CH), 76.9 (C), 72.8 (CH), 72.7 (C), 64.8
(CH), 61.5 (CH2), 61.0 (CH2), 52.3 (CH), 55.1 (CH), 52.3 (CH3),
29.2 (CH2), 13.6 (CH3), 12.9 (CH3); m/z (HRMS-ESI+) 529.0957
(M + H C25H26
79BrN2O6 requires 529.0969), 531.0951 (M + H
C25H26
81BrN2O6 requires 531.0949).
(1′R*,2′S*,3′S*,8a′S*)-Diethyl 1-acetyl-8′-bromo-2-oxo-3′,8a′-
dihydro-2′H-spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate
(3e). Yellow solid; 80 mg (83%); m.p. 108–110 °C; IR (νmax/
cm−1, CHCl3) 2981, 1744, 1710, 1636, 1561, 1466, 1370, 1308,
1272, 1191, 1023; NMR δH (400 MHz, d6-acetone) 8.22 (1H, d,
J = 8.2 Hz, ArH), 7.45–7.39 (2H, m, ArH), 7.21 (1H, td, J = 8.2, 1.4
Hz, ArH), 6.63 (1H, d, J = 7.1 Hz, N–CHvCH), 6.11 (1H, d, J =
6.5 Hz, CH–CHvCBr), 5.37 (1H, s, NCHC–Br), 5.05 (1H, d, J =
7.3 Hz, NCH(CO2Et)), 4.58 (1H, dd, J = 7.1, 6.5 Hz, NCHvCH),
4.29 (2H, q, J = 7.1 Hz, NCHCO2CH2CH3), 3.86 (1H, d, J = 7.3
Hz, CCH(CO2Et), 3.69 (2H, q, J = 7.1 Hz, CCH(CO2CH2CH3)),
2.66 (3H, s, NCOCH3), 1.31 (3H, t, J = 7.1 Hz, NCHCOCH2CH3),
0.69 (3H, t, J = 7.1 Hz, CCH(CO2CH2CH3)); NMR δC (100 MHz,
d6-acetone) 175.3 (C), 170.4 (C), 170.3 (C), 167.4 (C), 141.5 (C),
133.8 (CH), 129.4 (CH). 129.1 (CH), 125.4 (C), 124.7 (CH), 123.9
(CH), 115.9 (CH), 106.3 (C), 93.5 (CH), 74.3 (CH), 64.5 (CH), 63.8
(C), 61.7 (CH2), 61.2 (CH2), 53.6 (CH), 25.8 (CH3), 13.5 (CH3),
12.7 (CH3); m/z (HRMS-ESI+) 503.0800 (M + H C23H24
79BrN2O6
requires 503.0813), 505.0788 (M + H C23H24
81BrN2O6 requires
505.0792).
(1′S*,3′R*,8a′S*)-Ethyl 8′-bromo-2-oxo-3′,8a′-dihydro-2′H-
spiro[indoline-3,1′-indolizine]-3′-carboxylate (3f). Brown solid;
107 mg (81%); m.p. 144–146 °C; IR (νmax/cm
−1, CHCl3) 3434,
2962, 2361, 1732, 1621, 1472, 1374, 1261, 1106; NMR δH
(400 MHz, CDCl3) 8.55 (1H, s, NH), 7.33–7.28 (2H, m, ArH),
7.09–7.04 (1H, m, ArH), 6.97 (1H, d, J = 7.3 Hz, ArH), 6.25 (1H,
d, J = 7.2 Hz, NCHvCH), 6.07 (1H, d, J = 7.2 Hz, CHvCBr),
5.38 (1H, s, CH), 4.62 (1H, app.t, J = 7.2 Hz, NCHvCH), 4.44
(1H, dd, J = 8.4, 7.9 Hz, CHCO2Et), 4.29 (2H, q, J = 7.1 Hz,
CH2CH3), 2.52 (1H, dd, J = 13.4, 7.9 Hz, CHaHb), 2.22 (1H, dd,
J = 13.4, 8.4 Hz, CHaHb), 1.35 (3H, t, J = 7.1 Hz, CH2CH3); NMR
δC (100 MHz, CDCl3) 178.0 (C), 171.7 (C), 141.1 (C), 132.8 (CH),
130.6 (C), 128.6 (CH), 127.4 (CH), 123.6 (CH), 122.5 (CH), 110.0
(CH), 109.3 (C), 94.9 (CH), 71.5 (CH), 64.1 (CH), 61.8 (CH2),
60.9 (C), 37.7 (CH2), 14.2 (CH3); m/z (HRMS-ESI+) 389.0494 (M
+ H C18H18
79BrN2O3 requires 389.0501), 391.0476 (M + H
C18H18
81BrN2O3 requires 391.0480).
(1′S*,3′R*,8a′S*)-Ethyl 6′-cyano-2-oxo-3′,8a′-dihydro-2′H-spiro-
[indoline-3,1′-indolizine]-3′-carboxylate (3g) and (1′R*,3′R*,8a′
S*)-ethyl 6′-cyano-2-oxo-3′,8a′-dihydro-2′H-spiro[indoline-3,1′-
indolizine]-3′-carboxylate (3g′). Yellow solid; 90 mg (77%);
m.p. 188–190 °C; IR (νmax/cm
−1, CHCl3) 3203. 2981, 2938,
2203, 1731, 1643, 1621, 1574, 1485, 1469, 1391, 1133; NMR δH
(400 MHz, d6-acetone, 2 : 1 mixture of diastereoisomers, *indi-
cates minor where diﬀerent from major) 9.65 (1H, br s, NH),
9.50 (1H, br s, NH*), 7.35–7.20 (3H, m, ArH, NCCvCH),
7.07–6.95 (2H, m, ArH), 5.80 (1H, app dt, J = 10.0, 1.5 Hz,
CNC–CH*vCH), 5.67 (1H, app dt, J = 10.1, 1.5 Hz, CNC–
CHvCH), 5.06 (1H, t, J = 2.1 Hz, NCH*), 4.98–4.93 (2H, m,
CHCO2Et, NCH), 4.86 (1H, app t, J = 7.7 Hz, CH*CO2Et), 4.60
(1H, ddd, J = 10.0, 2.1, 1.0 Hz, CHvCH*–CH), 4.52 (1H, ddd,
J = 10.1, 2.1, 0.8 Hz, CHvCH–CH), 4.35–4.24 (2H, m, CH2CH3),
2.57 (1H, dd, J = 13.4, 8.6 Hz, CHa*), 2.48–2.43 (2H, m,
CH2CHCO2Et), 2.37 (1H, dd, J = 13.4, 7.7 Hz, CHb*), 1.30 (3H,
t, J = 7.1 Hz, CH2CH3); NMR δC (100 MHz, d
6-acetone) 179.3
(C), 176.5 (C), 171.8 (C), 171.6 (C), 147.8 (CH), 146.6 (CH),
143.5 (C), 142.3 (C), 132.1 (C), 129.8 (CH), 129.4 (CH), 127.9
(C), 126.4 (C), 124.7 (CH), 124.0 (CH), 123.7 (CH), 123.2 (CH),
123.0 (CH), 120.9 (C), 120.7 (C) 111.9 (CH), 111.5 (CH), 110.7
(CH), 110.2 (CH), 78.6 (C), 78.4 (C), 67.8 (CH), 67.4 (CH), 63.9
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(CH), 63.2 (CH), 62.4 (CH2), 62.3 (CH2), 37.2 (CH2), 34.9 (CH2),
14.5 (CH3); m/z (HRMS-ESI+) 358.1162 (M + Na C19H17N3NaO3
requires 358.1162).
(1′R*,3′S*,8a′R*)-Ethyl 6′-carbamoyl-2-oxo-3′,8a′-dihydro-2′H-
spiro[indoline-3,1′-indolizine]-3′-carboxylate (3h) and (1′R*,3′-
S*,8a′S*)-ethyl 6′-carbamoyl-2-oxo-3′,8a′-dihydro-2′H-spiro-
[indoline-3,1′-indolizine]-3′-carboxylate (3h′). Yellow solid;
109 mg (95%); m.p. 138–140 °C; IR (νmax/cm
−1, CHCl3) 3352.
2926, 2359, 2340, 1710, 1648, 1620, 1585, 1471, 1382, 1290,
1196, 1104; NMR δH (400 MHz, d
6-DMSO, 7 : 3 mixture of dia-
stereoisomers, *indicates minor where diﬀerent from major)
10.63 (1H, s, NH), 10.40 (1H, s, NH*), 7.38 (2H, s,
CHvCCONH2), 7.27–7.16 (4H, m, ArH), 7.02–6.84 (4H, m,
ArH), 6.54 (4H, br s, NH2), 6.28 (1H, dt, J = 10.2, 2.1 Hz,
NH2COC–CH*vCH), 6.14 (1H, dt, J = 10.2, 2.1 Hz, NH2COC–
CHvCH), 4.95 (1H, dd, J = 8.8, 7.4 Hz, CHCO2Et), 4.92 (1H,
dd, J = 8.8, 7.4 Hz, CH*CO2Et), 4.78 (2H, app dd, J = 2.1, 0.6
Hz, NCH), 4.38 (1H, ddd, J = 10.2, 2.1, 0.6 Hz, CHvCH*–CH),
4.35 (1H, ddd, J = 10.2, 2.1, 0.6 Hz, CHvCH–CH), 4.24 (4H, m,
CH2CH3), 2.47 (1H, dd, J = 13.3, 8.8 Hz, CHa*Hb), 2.35–2.17
(2H, m, CHb*, CHaHb), 1.29 (3H, t, J = 7.1 Hz, CH2CH3*), 1.27
(3H, t, J = 7.1 Hz, CH2CH3); NMR δC (100 MHz, d
6-DMSO)
179.3 (C), 176.6 (C), 172.2 (C), 172.1 (C), 167.4 (C), 167.3 (C),
143.0 (C), 142.6 (CH), 141.9 (C), 141.5 (CH), 132.0 (C) 129.0
(CH), 128.7 (CH), 128.0 (C) 124.8 (CH), 124.2 (CH), 124.1 (CH),
123.2 (CH), 122.1 (CH), 122.0 (CH) 110.0 (CH), 109.9 (CH),
109.1 (CH), 107.5 (CH), 101.1 (C), 101.0 (C), 68.1 (CH), 67.5
(CH), 63.5 (CH), 62.6 (CH), 61.8 (CH2), 61.7 (CH2), 55.6 (C),
55.4 (C), 36.5 (CH2), 34.3 (CH2), 14.6 (CH3), 14.5 (CH3); m/z
(HRMS-ESI+) 354.1442 (M + H C19H20N3O4 requires 354.1454).
(1′R*,3′S*,8a′R*)-Ethyl 6′-acetyl-2-oxo-3′,8a′-dihydro-2′H-spiro-
[indoline-3,1′-indolizine]-3′-carboxylate (3i) and (1′R*,3′S*,8a′
S*)-ethyl 6′-acetyl-2-oxo-3′,8a′-dihydro-2′H-spiro[indoline-3,1′-
indolizine]-3′-carboxylate (3i′). Brown solid, 97 mg (81%);
m.p. 118–120 °C; IR (νmax/cm
−1, CHCl3) 3434, 3010, 2447, 1731,
1621, 1573, 1472, 1373, 1251, 1180; NMR δH (400 MHz, CDCl3,
1 : 1.3 mixture of diastereoisomers, *indicates minor where
diﬀerent from major) 8.35 (1H, s, NH*), 8.21 (1 H, s, NH), 7.47
(1H, s, NCH*vCCOCH3), 7.42 (1H, s, NCHvCCOCH3),
7.27–6.94 (8H, m, ArH), 6.53 (1H, d, J = 10.3 Hz, (COCH3)
CHvCH–CH), 6.36 (1H, d, J = 10.3 Hz, (COCH3)CH*vCH–
CH), 5.18 (1H, t, J = 1.8 Hz, (COCH3)CHvCH–CH*), 5.05 (1H,
t, J = 1.8 Hz, (COCH3)CHvCH–CH), 4.81 (1H, t, J = 7.8 Hz,
CHCO2Et), 4.67 (1H, dd, J = 10.3, 1.8 Hz, (COCH3)CHvCH–
CH) 4.61 (1H, t, J = 7.8 Hz, CH*CO2Et) 4.53 (1H, dd, J = 10.3,
1.8 Hz, (COCH3)CHvCH*–CH), 4.38–4.30 (4H, m, CH2CH3),
2.70–2.58 (2H, m, CH–CHaCHb), 2.45–2.33 (2H, m, CH–
CHaCHb), 2.18 (3H, s, COCH3*), 2.13 (3H, s, COCH3), 1.41–1.34
(3H, m, CH2CH3); NMR δC (100 MHz, CDCl3) 191.8 (C), 179.6
(C), 176.8 (C), 171.2 (C), 170.6 (C), 146.2 (CH), 144.3 (CH),
141.6 (C), 140.3 (C), 130.7 (C), 129.2 (CH), 128.9 (CH), 126.8
(C), 123.9 (CH), 123.7 (CH), 123.5 (CH), 123.2 (CH), 122.9 (CH),
122.8 (CH), 122.6 (CH), 110.4 (CH), 110.3 (CH), 108.7 (CH),
68.1 (CH), 67.1 (CH), 63.3 (CH), 62.8 (CH), 62.4 (CH2), 62.2
(CH2), 58.8 (C), 58.4 (C), 36.9 (CH2), 34.4 (CH2), 14.2 (CH3); m/z
(HRMS-ESI+) 353.1498 (M + H C20H21N2O4 requires 353.1501).
(1′R*,3′S*,8a′S*)-3′-Acetyl-8′-bromo-3′,8a′-dihydro-2′H-spiro
[indoline-3,1′-indolizin]-2-one (3j). Brown solid; 63 mg
(76%); m.p. 126–128 °C; IR (νmax/cm
−1, CHCl3) 3438, 3011,
2928, 2437, 1780, 1721, 1622, 1471, 1426, 1390, 1240, 1170;
NMR δH (400 MHz, d
6-DMSO) 10.53 (1H, s, NH), 7.27–7.19 (2H,
m, 2× ArH), 6.96 (1H, td, J = 7.6, 1.0 Hz, ArH), 6.86 (1H, d, J =
7.6 Hz, ArH), 6.43 (1H, d, J = 7.0 Hz, CH–CHvCBr), 6.09 (1H,
d, J = 7.0 Hz, N–CHvCH), 4.88 (1H, s, NCH), 4.70 (1H, t, J = 7.0
Hz, NCHvCH), 4.49 (1H, t, J = 6.8 Hz, CHCOCH3), 2.19 (3H, s,
COCH3), 2.11–2.06 (2H, m, CHaHb); NMR δC (100 MHz, d
6-
DMSO) 207.3 (C), 177.7 (C), 142.8 (C), 135.2 (CH), 131.3 (C),
128.7 (CH), 128.2 (CH), 123.8 (CH), 121.8 (CH), 109.9 (CH),
108.0 (C), 93.3 (CH), 71.7 (CH), 70.5 (CH), 61.3 (C), 36.4 (CH2),
26.7 (CH3); m/z (HRMS-ESI+) 359.0370 (M + H C17H16
79BrN2O2
requires 359.0395), 361.0359 (M + H C17H16
81BrN2O2 requires
361.0375).
(2′S*,3′S*,8a′S*)-Diethyl 8′-fluoro-2-oxo-3′,8a′-dihydro-2′H-
spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate (3k). Yellow
oil; 80 mg (87%); IR (νmax/cm
−1, CHCl3) 3691, 3440, 3010,
1736, 1620, 1597, 1472, 1391, 1314, 1192, 1025; NMR δH
(400 MHz, d6-acetone) 9.66 (1H, br s, NH), 7.26–7.22 (2H, m,
ArH), 6.97–6.91 (2H, m, ArH), 6.35–6.32 (1H, m, N–CHvCH),
5.39–5.34 (1H, m, CH–CHvCF), 5.17 (1H, s, NCHC–F), 5.03
(1H, dd, J = 7.4, 1.2 Hz, NCH(CO2Et)), 4.54–4.49 (1H, m,
NCHvCH), 4.27 (2H, q, J = 7.1 Hz, NCHCO2CH2CH3),
3.81–3.66 (3H, m, NCH(CO2Et)CH(CO2Et), NCH(CO2Et)CH-
(CO2CH2CH3)), 1.29 (3H, t, J = 7.1 Hz, NCHCOCH2CH3), 0.70
(3H, t, J = 7.1 Hz, NCH(CO2Et)CH(CO2CH2CH3)); NMR δC
(100 MHz, d6-acetone) 174.9 (C), 170.9 (C), 168.1 (C), 149.3 (d,
JC–F = 252 Hz, C), 143.0 (C), 130.5 (d, JC–F = 4 Hz, CH), 129.0
(CH), 126.6 (C), 124.6 (CH), 121.3 (CH), 109.6 (CH), 103.1 (d,
JC–F = 14 Hz, CH), 91.1 (d, JC–F = 5 Hz, CH), 68.0 (d, JC–F = 33
Hz, CH), 65.3 (d, JC–F = 1 Hz, CH), 62.6 (d, JC–F = 3 Hz, C), 61.5
(CH2), 60.9 (CH2), 52.9 (CH), 13.6 (CH3), 12.8 (CH3); m/z
(HRMS-ESI+) 401.1507 (M + H C21H22FN2O5 requires
401.1507).
(1′R*,2′S*,3′S*,8a′R*)-Diethyl 2-oxo-3′,5′,6′,7′,8′,8a′- hexahydro-
2′H-spiro[indoline-3,1′-indolizine]-2′,3′-dicarboxylate (3l).
Following the general procedure described above but the
product was not stable to chromatography on silica gel, so the
crude cycloadduct 4 was reduced without purification using
the following procedure.
Crude cycloadduct 4 (75 mg) and RANEY® nickel (10 mol%)
were dissolved in anhydrous ethyl acetate (4 mL), under
argon. The atmosphere was replaced with H2 and the mixture
stirred until reduction was complete by TLC analysis and then
filtered through a pad of Celite. The filtrate was concentrated
in vacuo and purified via column chromatography (EtOAc–
petrol; 1/4) to give spiroindolizidine 3l as a yellow oil; 48 mg
(63%); IR (νmax/cm
−1, CHCl3) 3440, 3198, 2942, 1732, 1621,
1471, 1373, 1339, 1319, 1184, 1097; NMR δH (400 MHz, CDCl3)
8.66 (1H, br s, NH), 7.31 (1H, d, J = 7.6 Hz, ArH), 7.22 (1H, td,
J = 7.6, 1.0 Hz, ArH), 7.00 (1H, t, J = 7.6 Hz, ArH), 6.92 (1H, d, J =
7.6 Hz, ArH), 4.59 (1H, d, J = 5.6 Hz, NCHCO2Et), 4.35–4.20 (2H,
m, NCH(COCH2CH3)), 4.00 (1H, d, J = 5.6 Hz, NCH(CO2Et)CH),
3.81–3.61 (2H, m, CH(COCH2CH3)), 3.41 (1H, dd, J = 10.9, 2.4
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2013 Org. Biomol. Chem., 2013, 11, 6502–6509 | 6507
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
A
ug
us
t 2
01
3.
 D
ow
nl
oa
de
d 
on
 2
8/
03
/2
01
4 
13
:0
9:
17
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Hz, NCHC)), 3.09 (1H, d, J = 9.5 Hz, CHaHb), 2.45 (1H, t, J = 9.5
Hz, CHaHb), 1.64–1.53 (2H, m, CHaHb, CHaHb), 1.42–1.12 (6H,
m, CHaHb, CHaHb, CHaCHb, CH2CH3), 0.74–0.64 (4H, m,
CH2CH3, CHaCHb); NMR δC (100 MHz, CDCl3) 178.4 (C), 172.4
(C), 143.1 (C), 131.7 (C), 128.2 (CH), 126.5 (C), 125.8 (CH), 122.2
(CH), 109.4 (CH), 67.7 (CH), 64.1 (CH), 60.9 (CH2), 60.6 (CH2),
60.0 (C), 54.2 (CH), 47.5 (CH2), 25.9 (CH2), 25.3 (CH2), 22.6
(CH2), 14.4 (CH3), 13.3 (CH3); m/z (HRMS-ESI+) 387.1908 (M + H
C21H27N2O5 requires 387.1920).
(1′S*,2′R*,3′R*,8a′R*)-Ethyl 8′-bromo-3′-cyano-2-oxo-3′,8a′-dihydro-
2′H-spiro[indoline-3,1′-indolizine]-2′-carboxylate (3m). White solid;
145 mg (72%); m.p. 159–161 °C (acetone); IR (νmax/cm
−1,
CHCl3) 3691, 3439, 3009, 2482, 2245, 1735, 1640, 1621, 1569,
1485, 1378, 1191; NMR δH (400 MHz, d
6-acetone) 9.74 (1H, br
s, NH), 7.28 (1H, app t, J = 7.6 Hz, ArH), 7.22 (1H, d, J = 7.3 Hz,
ArH), 7.01–6.91 (2H, m, ArH), 6.67 (1H, d, J = 7.2, N–CHvCH),
6.12 (1H, d, J = 6.4 Hz, CH–CHvCBr), 5.48 (1H, d, J = 6.4 Hz,
NCHCN, 5.25 (1H, s, NCHC–Br), 4.72 (1H, app t, J = 6.4 Hz,
NCHvCH), 3.77 (1H, d, J = 6.4 Hz, CHCO2CH2CH3), 3.72 (2H,
q, J = 7.1 Hz, CCH(CO2CH2CH3)), 0.74 (3H, t, J = 7.1 Hz,
NCHCOCH2CH3); NMR δC (100 MHz, d
6-DMSO) 176.1 (C),
167.9 (C), 144.6 (C), 132.8 (CH), 130.3 (CH), 129.1 (CH), 126.7
(C), 125.5 (CH), 122.3 (CH), 119.1 (C), 110.6 (CH), 109.1
(C), 96.7 (CH), 72.9 (CH), 63.8 (C), 62.3 (CH2), 55.6 (CH), 54.9
(CH), 13.7 (CH3); m/z (HRMS-ESI+) 436.0273 (M + Na
C19H16
79BrN3NaO3 requires 436.0273), 438.0256 (M + Na
C19H16
81BrN3NaO3 requires 438.0256).
(1′S*,2′R*,3′R*,8a′R*)-Ethyl 8′-bromo-2-oxo-3′-phenyl-3′,8a′-dihydro-
2′H-spiro[indoline-3,1′-indolizine]-2′-carboxylate (3n). White solid;
149 mg (70%); m.p. 176–178 °C (acetone); IR (νmax/cm
−1,
CHCl3) 3692, 3441, 3009, 1731, 1601, 1562, 1484, 1379, 1247,
1117, 1027; NMR δH (400 MHz, d
6-acetone) 9.71 (1H, br s, NH),
7.51–7.41 (5H, m, ArH), 7.36–7.25 (2H, m, ArH), 7.01 (1H, td,
J = 7.7, 0.8 Hz, ArH), 6.97 (1H, d, J = 7.7 Hz, ArH), 6.32 (1H, d, J =
6.7 Hz, N–CHvCH), 6.07 (1H, d, J = 6.7 Hz, CH–CHvCBr), 5.43
(1H, d, J = 8.5 Hz, NCHPh, 4.51 (1H, app t, J = 6.7 Hz,
CHvCHN), 3.78 (1H, dq, J = 10.8, 7.1 Hz, CHaHb), 3.67 (1H, dq,
J = 10.8, 7.1 Hz, CHaHb), 3.4 (1H, d, J = 8.5 Hz, CHCO2Et), 0.77
(3H, t, J = 7.1 Hz, CH3); NMR δC (100 MHz, d
6-acetone) 176.6 (C),
169.3 (C), 144.5 (C), 143.2 (C), 134.6 (CH), 130.0 (CH), 129.9
(CH), 129.4 (CH), 128.7 (CH), 127.5 (C), 127.2 (CH), 125.6 (CH),
122.2 (CH), 110.4 (CH), 108.3 (C), 94.1 (CH), 73.7 (CH),
68.1 (CH), 64.8 (C), 61.6 (CH2), 59.4 (CH), 13.8 (CH3);
m/z (HRMS-ESI+) 465.0800 (M + H C24H22
79BrN2O3
requires 465.0808), 467.0786 (M + H C24H22
81BrN2O3 requires
465.0793).
Diethyl 2-(2-oxoindolin-3-ylidene)succinate 5. Method as
cycloaddition, but ethanol was used as solvent and reaction
performed at 50 °C. Yellow oil (60%); NMR δH (400 MHz,
CDCl3, 5 : 1 mixture of diastereoisomers, only major diastereo-
isomer peaks are quoted) (νmax/cm
−1, CHCl3) 3446, 3011, 2986,
1726, 1617, 1470, 1370, 1334, 1295, 1192; NMR δH (400 MHz,
CDCl3) 8.38 (1H, s, NH), 7.66 (1H, d, J = 8.0 Hz, ArH), 7.29 (1H,
td, J = 8.0, 1.2 Hz, ArH), 6.98 (1H, td, J = 8.0, 1.2 Hz, ArH), 6.85
(1H, d, J = 8.0 Hz, ArH), 4.43 (2H, q, J = 7.2 Hz, CH2CH3), 4.41
(2H, s, CH2CO2Et), 4.22 (2H, q, J = 7.2 Hz, CH2CH3), 1.40 (3H,
t, J = 7.2 Hz, CH2CH3), 1.29 (3H, t, J = 7.2 Hz, CH2CH3); NMR
δC (100 MHz, CDCl3) 169.7 (C), 169.2 (C), 167.4 (C), 141.0 (C),
135.0 (C), 130.9 (CH), 129.4 (C), 125.1 (CH), 122.3 (CH), 120.8
(C), 109.9 (CH), 61.9 (CH2), 61.2 (CH2), 34.7 (CH2), 14.2 (CH3),
14.0 (CH3); m/z (HRMS-ESI+) 326.0982 ([M + Na] 100%)
requires C16H17NO5Na
+ 326.0999.
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